Khan M Z, Freshney R I, McNicol A M, Murray A M
CRC Department of Medical Oncology, University of Glasgow, U.K.
Ann Oncol. 1993 Jun;4(6):499-507. doi: 10.1093/oxfordjournals.annonc.a058562.
Hexamethylene bisacetamide (HMBA), sodium butyrate (NaBt), and cyclic AMP (cAMP) have been shown to induce differentiation, which may regulate tumour growth differently from conventional cytotoxic drugs. It was the intention in the present study to determine whether alterations could be induced in the phenotype of small cell lung cancer (SCLC) cell lines with HMBA, NaBt and cAMP, and whether these alterations would correlate with reduced growth in vivo, implying a phenotypic shift from malignancy towards differentiation.
The cell lines were NCI-H69, H187 and H128. The activity of dopa decarboxylase (DDC), the BB isozyme of creatine kinase (CK-BB), the synthesis of bombesin-like peptide (BLI), and the presence of neurone specific enolase (NSE) and chromogranin were used as markers of the small cell phenotype. Clonogenicity in suspension in agar, and growth as xenografts in nude mice, were used as malignancy-associated properties. Cell proliferation in vitro was determined by cell counting and growth curve analysis.
HMBA, NaBt and cAMP were found to be reversibly cytostatic in liquid culture and pre-exposure reduced the cloning efficiency in agar by 60%-80%. Growth as xenografts was inhibited (three- to five-fold increase in the tumour doubling time), most significantly by NaBt. Effects of phenotypic markers were more complex. The most significant were a two-fold reduction in DDC with NaBt and HMBA, a 50% increase in CK-BB with cAMP, and a 70%-100% increase in secreted BLI with HMBA and cAMP, in NCI-H69 cells. No significant effects were seen on NSE and chromogranin. There was little sign of an interaction with adriamycin and vincristine, although a slight increase was observed in the ID50 of VP-16 following treatment with cAMP.
NaBt, HMBA and cAMP were cytostatic and inhibited tumour growth, but there was no coordinated response in marker expression that would confirm phenotypic alteration indicative of differentiation. The problem of defining differentiation in SCLC further complicated the analysis. The possibility remains of combining these agents with conventional cytotoxics as there appears to be little antagonistic effect, and other studies have suggested synergism may be possible with correct scheduling.
已证实六亚甲基双乙酰胺(HMBA)、丁酸钠(NaBt)和环磷酸腺苷(cAMP)可诱导分化,其调节肿瘤生长的方式可能与传统细胞毒性药物不同。本研究旨在确定HMBA、NaBt和cAMP是否能诱导小细胞肺癌(SCLC)细胞系的表型改变,以及这些改变是否与体内生长减缓相关,这意味着从恶性表型向分化表型的转变。
所用细胞系为NCI-H69、H187和H128。多巴脱羧酶(DDC)活性、肌酸激酶BB同工酶(CK-BB)、蛙皮素样肽(BLI)的合成以及神经元特异性烯醇化酶(NSE)和嗜铬粒蛋白的存在被用作小细胞表型的标志物。琼脂悬液中的克隆形成能力以及裸鼠体内异种移植瘤的生长情况被用作与恶性相关的特性。通过细胞计数和生长曲线分析来测定体外细胞增殖。
发现HMBA、NaBt和cAMP在液体培养中具有可逆的细胞生长抑制作用,预先暴露可使琼脂中的克隆效率降低60%-80%。异种移植瘤的生长受到抑制(肿瘤倍增时间增加三到五倍),其中以NaBt的抑制作用最为显著。表型标志物的影响更为复杂。在NCI-H69细胞中,最显著的变化是NaBt和HMBA使DDC降低两倍,cAMP使CK-BB增加50%,HMBA和cAMP使分泌的BLI增加70%-100%。对NSE和嗜铬粒蛋白未见显著影响。与阿霉素和长春新碱几乎没有相互作用的迹象,不过用cAMP处理后,VP-16的半数抑制浓度(ID50)略有增加。
NaBt、HMBA和cAMP具有细胞生长抑制作用并能抑制肿瘤生长,但标志物表达中没有协同反应来证实表明分化的表型改变。小细胞肺癌中分化的定义问题使分析进一步复杂化。由于似乎几乎没有拮抗作用,且其他研究表明正确的用药方案可能产生协同作用,因此仍有可能将这些药物与传统细胞毒性药物联合使用。